Clinical Trial Update: Durvalumab as Consolidation for Patients LS-SCLC [Phase 2]

View source ↗

Summary

Durvalumab is being studied as consolidation therapy for limited-stage small cell lung cancer in a Phase 2 trial. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Qian Chu | Conditions: Small Cell Lung Cancer Limited Stage | Phase 2 | Status: RECRUITING